HK inno.N expands GERD drug footprint in 6 North African countries

HK inno.N is accelerating the global expansion of its innovative gastroesophageal reflux disease (GERD) treatment, K-CAB, by adding new markets across North Africa.

The company said it has signed a new export agreement with Saudi Arabia’s leading pharmaceutical company, Tabuk Pharmaceuticals, to supply finished K-CAB products to six additional North African countries, including Egypt.

This latest deal builds on a previous agreement signed last year, under which HK inno.N and Tabuk Pharmaceuticals partnered to distribute K-CAB in 10 countries across the Middle East and North Africa (MENA) region. The expanded agreement will see K-CAB enter Egypt, Sudan, Ethiopia, Morocco, Yemen, and Libya.

Unlike traditional licensing deals, HK inno.N is expanding K-CAB’s international presence primarily through the export of finished products. With the latest agreement, the drug is now available in 53 countries outside of Korea, marking a significant milestone in the company’s international growth strategy.

Tabuk Pharmaceuticals, known for its strong distribution network and marketing expertise across the MENA region, is expected to play a crucial role in establishing K-CAB’s presence and driving its market adoption in North Africa.

“With this agreement, K-CAB has now entered 53 countries, surpassing the halfway point toward our goal of reaching 100 countries by 2028,” HK inno.N CEO Kwak Dal-won said.. “We will continue working closely with our partners worldwide to establish K-CAB as a paradigm-shifting treatment for GERD.”

Tabuk Pharmaceuticals CEO Ismail Shehada also said, “Our partnership with HK inno.N is a cornerstone of our growth strategy, and we are excited not only to expand into more countries but also to strengthen our cooperation by broadening the product portfolio in the future.”

This aligns with Tabuk’s shared mission to improve patient access to treatment and deliver innovative healthcare solutions, Shehada added.